30 results match your criteria: "and Beth Israel Medical Centers[Affiliation]"

Photodermatoses are relatively uncommon, but most dermatologists will have to diagnose and treat them at some point. This article highlights several photodermatoses, their common symptoms and possible. Unfortunately, sunscreens marketed in the United States do not presently contain agents that are effective against longer wavelengths.

View Article and Find Full Text PDF

Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon. Because of its immunomodulating effects levamisole has been used in a wide range of diseases with and without success.

View Article and Find Full Text PDF

Medical backgrounder: psoriasis.

Drugs Today (Barc)

December 2002

Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York, NY, U.S.A.

Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Psoriatic lesions are extremely characteristic of the disease, which allows for simple diagnosis. A clear understanding of the pathogenesis of psoriasis does not yet exist.

View Article and Find Full Text PDF

Neurocutaneous disorders.

Dermatol Clin

July 2002

Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA.

"Neurocutaneous disorders" is a catch-all phrase that includes all disorders involving both the nervous systems and the skin. These may range from disorders in which cutaneous findings are essential to diagnosis to those with less significant involvement of the skin. Because of the variety of disorders that involve the skin and the nervous system, this article reviews a few of the more essential diagnoses, and those with recent advancements in diagnosis and management.

View Article and Find Full Text PDF

This article, the second in a 2-part series, will review interleukin 10 (IL-10) administration, the T-cell receptor mimic peptide, and CTLA4Ig. We also will review 4 of the most promising therapies currently being investigated for the treatment of psoriasis: infliximab, etanercept, efalizumab, and alefacept.

View Article and Find Full Text PDF